News Focus
News Focus
Followers 43
Posts 5340
Boards Moderated 0
Alias Born 12/05/2021

Re: jesster64 post# 776460

Thursday, 07/17/2025 1:47:00 PM

Thursday, July 17, 2025 1:47:00 PM

Post# of 823820

slave1, first of all a big Thank You for your insights. So to dumb it down for investors like me, NWBO submitted dc-vax initially for glioblastoma treatment, using the old manufacturing system. Since then, the MHRA has considered the success of dc-vax for other types of cancer being treated under compassionate care and started working with NWBO to expand the scope beyond just for glioblastoma. They will use Sl87 to justify this. The submission was under the old manufacturing process, but they upped the scope to include flaskworks and advent as the same source allowing for flaskworks to be phased in. Nice is not acting until they receive smpc, which is being written in coordination with NWBO as we speak. NWBO will remain silent until smpc is locked. So the extra time its taken for approval is due to the scope of dc-vax for multiple cancers. Am I getting it so far?

wild and absurd speculation based on fantasy and imagination.
The speculation here that DCVAX could be approved for all solid tumors without additional trials just has to stop; the notion is simply insane.

Gilead, you invested $21 billion to acquire Immunomedics, gaining access to the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) to treat solid tumors? Sorry you can start depreciating on your investment for at least the UK now by a significant number because we, the MHRA, just granted DCVAX for no reason without additional trials approval for ALL solid tumors. Sure MHRA we will bend to the awesomeness of DCVAX and understand this completely that DCVAX will be our competitor for solid tumor breast cancer without any medical evidence and due process and not sue your ass back and forth at all.

Just nuts NUTS
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News